Similarly, a retrospective American study involving 184 IBD patients with a prior history of cancer reported an incidence of new or recurrent cancer of 4.2 per 1000 person-years among those exposed to TNF-α antagonists. The gene discussed is TNF; the disease is inflammatory bowel disease.